1. Duration of Dual Antiplatelet Therapy

2. European and US Guidelines

3. PCI-CURE CV Death or MI

4. CHARISMA Instantaneous Hazard for Moderate or Severe Bleeding

5. CHARISMA Primary End Point

6. TRILOGY-ACS Primary Efficacy End Point to 30 Months (Age < 75 years)

7. DAPT Trial Total Enrollment

9. DES vs BMS

10. DAPT Trials Unanswered Questions

11. OPTIMIZE Second-generation DES Effect of Short- and Long-term DAPT

12. New Trials With Ticagrelor

15. Abbreviations

16. Abbreviations (cont)

17. Abbreviations (cont)

18. References

19. References (cont)

20. References (cont)

21. References (cont)